Advertisement

Topics

Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer

14:04 EDT 29 Jun 2017 | SCRIP

As the RCC field braces for another paradigm change, early studies combining tyrosine kinase inhibitors with PD-1/L1 inhibitors suggest the...

      

Related Stories

 

Original Article: Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer

NEXT ARTICLE

More From BioPortfolio on "Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer"

Advertisement
Quick Search
Advertisement
Advertisement